These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 33993366)

  • 1. Imaging features of gadoxetic acid-enhanced MR imaging for evaluation of tumor-infiltrating CD8 cells and PD-L1 expression in hepatocellular carcinoma.
    Sun L; Mu L; Zhou J; Tang W; Zhang L; Xie S; Chen J; Wang J
    Cancer Immunol Immunother; 2022 Jan; 71(1):25-38. PubMed ID: 33993366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic performance of gadoxetic acid-enhanced liver MR imaging in the detection of HCCs and allocation of transplant recipients on the basis of the Milan criteria and UNOS guidelines: correlation with histopathologic findings.
    Lee DH; Lee JM; Baek JH; Shin CI; Han JK; Choi BI
    Radiology; 2015 Jan; 274(1):149-60. PubMed ID: 25203131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatocellular carcinoma: preoperative gadoxetic acid-enhanced MR imaging can predict early recurrence after curative resection using image features and texture analysis.
    Ahn SJ; Kim JH; Park SJ; Kim ST; Han JK
    Abdom Radiol (NY); 2019 Feb; 44(2):539-548. PubMed ID: 30229421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A radiomics-based biomarker for cytokeratin 19 status of hepatocellular carcinoma with gadoxetic acid-enhanced MRI.
    Wang W; Gu D; Wei J; Ding Y; Yang L; Zhu K; Luo R; Rao SX; Tian J; Zeng M
    Eur Radiol; 2020 May; 30(5):3004-3014. PubMed ID: 32002645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imaging biomarkers for well and moderate hepatocellular carcinoma: preoperative magnetic resonance image and histopathological correlation.
    Huang K; Dong Z; Cai H; Huang M; Peng Z; Xu L; Jia Y; Song C; Li ZP; Feng ST
    BMC Cancer; 2019 Apr; 19(1):364. PubMed ID: 30999947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
    Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
    Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Added value of hepatobiliary phase gadoxetic acid-enhanced MRI for diagnosing hepatocellular carcinoma in high-risk patients.
    Phongkitkarun S; Limsamutpetch K; Tannaphai P; Jatchavala J
    World J Gastroenterol; 2013 Dec; 19(45):8357-65. PubMed ID: 24363528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differentiation of intrahepatic mass-forming cholangiocarcinoma from hepatocellular carcinoma on gadoxetic acid-enhanced liver MR imaging.
    Kim R; Lee JM; Shin CI; Lee ES; Yoon JH; Joo I; Kim SH; Hwang I; Han JK; Choi BI
    Eur Radiol; 2016 Jun; 26(6):1808-17. PubMed ID: 26373763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Immune Response on Outcomes in Hepatocellular Carcinoma: Association With Vascular Formation.
    Itoh S; Yoshizumi T; Yugawa K; Imai D; Yoshiya S; Takeishi K; Toshima T; Harada N; Ikegami T; Soejima Y; Kohashi K; Oda Y; Mori M
    Hepatology; 2020 Dec; 72(6):1987-1999. PubMed ID: 32112577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imaging Features of Gadoxetic Acid-enhanced and Diffusion-weighted MR Imaging for Identifying Cytokeratin 19-positive Hepatocellular Carcinoma: A Retrospective Observational Study.
    Choi SY; Kim SH; Park CK; Min JH; Lee JE; Choi YH; Lee BR
    Radiology; 2018 Mar; 286(3):897-908. PubMed ID: 29166246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiparametric assessment of microvascular invasion in hepatocellular carcinoma using gadoxetic acid-enhanced MRI.
    Fujita N; Ushijima Y; Ishimatsu K; Okamoto D; Wada N; Takao S; Murayama R; Itoyama M; Harada N; Maehara J; Oda Y; Ishigami K; Nishie A
    Abdom Radiol (NY); 2024 May; 49(5):1467-1478. PubMed ID: 38360959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preoperative gadoxetic acid-enhanced MRI for predicting microvascular invasion in patients with single hepatocellular carcinoma.
    Lee S; Kim SH; Lee JE; Sinn DH; Park CK
    J Hepatol; 2017 Sep; 67(3):526-534. PubMed ID: 28483680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Performance of gadoxetic acid MRI and diffusion-weighted imaging for the diagnosis of early recurrence of hepatocellular carcinoma.
    Rimola J; Forner A; Sapena V; Llarch N; Darnell A; Díaz A; García-Criado A; Bianchi L; Vilana R; Díaz-González Á; Ayuso C; Bruix J; Reig M
    Eur Radiol; 2020 Jan; 30(1):186-194. PubMed ID: 31372783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gadoxetic acid-enhanced MRI as a predictor of recurrence of HCC after liver transplantation.
    Lee S; Kim KW; Jeong WK; Kim MJ; Choi GH; Choi JS; Song GW; Lee SG
    Eur Radiol; 2020 Feb; 30(2):987-995. PubMed ID: 31471754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Value of gadoxetic acid-enhanced MRI and diffusion-weighted imaging in the differentiation of hypervascular hyperplastic nodule from small (<3 cm) hypervascular hepatocellular carcinoma in patients with alcoholic liver cirrhosis: A retrospective case-control study.
    Kim SS; Kim SH; Song KD; Choi SY; Heo NH
    J Magn Reson Imaging; 2020 Jan; 51(1):70-80. PubMed ID: 31062483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MR-imaging features of hepatocellular carcinoma capsule appearance in cirrhotic liver: comparison of gadoxetic acid and gadobenate dimeglumine.
    Dioguardi Burgio M; Picone D; Cabibbo G; Midiri M; Lagalla R; Brancatelli G
    Abdom Radiol (NY); 2016 Aug; 41(8):1546-54. PubMed ID: 27052455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suboptimal hepatobiliary phase image in gadoxetic acid-enhanced liver MRI for the evaluation of the HCC: Predictive factors.
    Ryeom H; Chang Y; Park SY; Cho SH; Yeo B; Je H; Baek J
    Medicine (Baltimore); 2023 Nov; 102(46):e36176. PubMed ID: 37986292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T1 mapping combined with Gd-EOB-DTPA-enhanced magnetic resonance imaging in predicting the pathologic grading of hepatocellular carcinoma.
    Chen CY; Chen J; Xia CC; Huang ZX; Song B
    J Biol Regul Homeost Agents; 2017; 31(4):1029-1036. PubMed ID: 29254310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of small hepatocellular carcinoma using gadoxetic acid-enhanced MRI: Is the addition of diffusion-weighted MRI at 3.0T beneficial?
    Zhao XT; Li WX; Chai WM; Chen KM
    J Dig Dis; 2014 Mar; 15(3):137-45. PubMed ID: 24354621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatocellular carcinoma detection: diagnostic performance of a simulated abbreviated MRI protocol combining diffusion-weighted and T1-weighted imaging at the delayed phase post gadoxetic acid.
    Besa C; Lewis S; Pandharipande PV; Chhatwal J; Kamath A; Cooper N; Knight-Greenfield A; Babb JS; Boffetta P; Padron N; Sirlin CB; Taouli B
    Abdom Radiol (NY); 2017 Jan; 42(1):179-190. PubMed ID: 27448609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.